Preparation, characterization, and in vitro anti-inflammatory evaluation of novel water soluble kamebakaurin/hydroxypropyl-β-cyclodextrin inclusion complex

Journal of Molecular Structure

Volumn 1130, Issue , 2017, Pages 319-326

  Raza, Aun ^a   Sun, Huifang ^a   Bano, Shumaila ^b   Zhao, Yingying ^a   Xu, Xiuquan ^a   Tang, Jian ^a  

^a JIANGSU UNIVERSITY   (China)

^b THE ISLAMIA UNIVERSITY OF BAHAWALPUR   (Pakistan)

Author keywords

Anti inflammatory; Characterization; Hydroxypropyl cyclodextrin; Inclusion complex; Kamebakaurin; Solubility

Indexed keywords

CYCLODEXTRINS; SOLUBILITY;

ANTI-INFLAMMATORIES; ANTI-INFLAMMATORY EFFECTS; ANTI-INFLAMMATORY STUDIES; CHARACTERIZATION TECHNIQUES; INCLUSION COMPLEX; KAMEBAKAURIN; SPECTROSCOPIC CHARACTERISTICS; WATER SOLUBILITIES;

CHARACTERIZATION;

EID: 84992561480     PISSN: 00222860     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molstruc.2016.10.059     Document Type: Article

References (42)

1. [1] Tang, J., Sun, H., Olatunji, O., Ouyang, Z., Chen, H., Wang, M., A new diterpenoid glucoside from aerial parts of Rabdosia excisa. Chem. Nat. Compd. 6 (2015), 1107–1110.
2. [2] Tang, J., Ma, R.L., Li, Q.Q., Jiang, C.B., Chen, R., Ouyang, Z., Chen, H.S., Wang, M., Ultrasound-assisted extraction of kamebakaurin from Rabdosia excisa by response surface methodology. Chem. Res. Chin. Univ. 29 (2013), 1072–1077.
3. [3] Hwang, B.Y., Lee, J.H., Koo, T.H., Kim, H.S., Hong, Y.S., Ro, J.S., Lee, K.S., Lee, J.J., Kaurane diterpenes from Isodon japonicus inhibit nitric oxide and prostaglandin E2 production and NF-κB activation in LPS-stimulated macrophage RAW264.7 cells. Planta Med. 67 (2001), 406–410.
4. [4] Kim, J.Y., Kim, H.S., Kim, Y.J., Lee, H.K., Kim, J.S., Kang, J.S., Hong, J.T., Kim, Y., Hwang, B.Y., Han, S.-B., Inhibition of TAK1 by kamebakaurin in dendritic cells. Int. Immunopharmacol. 15 (2013), 138–143.
5. [5] Lee, J.H., Choi, J.K., Noh, M.S., Hwang, B.Y., Hong, Y.S., Lee, J.J., Anti-inflammatory effect of kamebakaurin in in vivo animal models. Planta Med. 70 (2004), 526–530.
6. [6] Kim, B.W., Koppula, S., Kim, I.S., Lim, H.W., Hong, S.M., Han, S.-D., Hwang, B.Y., Choi, D.-K., Anti-neuroinflammatory activity of kamebakaurin from Isodon japonicus via inhibition of c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase pathway in activated microglial cells. J. Pharmacol. Sci. 116 (2011), 296–308.
7. [7] Lee, J.H., Koo, T.H., Hwang, B.Y., Lee, J.J., Kaurane diterpene, kamebakaurin, inhibits NF-κB by directly targeting the DNA-binding activity of p50 and blocks the expression of antiapoptotic NF-κB target genes. J. Biol. Chem. 277 (2002), 18411–18420.
8. [8] Paris, D., Patel, N., Quadros, A., Linan, M., Bakshi, P., Ait-Ghezala, G., Mullan, M., Inhibition of Aβ production by NF-κB inhibitors. Neurosci. Lett. 415 (2007), 11–16.
9. [9] Xu, W., Sun, J., Zhang, T.T., Ma, B., Chen, D.W., He, Z.G., Determination of equilibrium solubility of oridonin and its apparent oil/water partition coefficient by HPLC. J. Shenyang Pharm. Univ., 4, 2007, 007.
10. [10] García, P.A., De Oliveira, A.B., Batista, R., Occurrence, biological activities and synthesis of kaurane diterpenes and their glycosides. Molecules 12 (2007), 455–483.
11. [11] Majeed M., Kumar A., Nagabhushanam K., Prakash S., Process for preparing water soluble diterpenes and their applications, Google Patents, (2005).
12. [12] Adibkia, K., Barzegar-Jalali, M., Maheri-Esfanjani, H., Ghanbarzadeh, S., Shokri, J., Sabzevari, A., Javadzadeh, Y., Physicochemical characterization of naproxen solid dispersions prepared via spray drying technology. Powder Technol. 246 (2013), 448–455.
13. [13] Burton, L., Ying, W., Gandhi, R., West, R., Huang, C., Zhou, S., Shah, K., Chen, J., Shen, X., Development of a precipitation-resistant solution formulation to increase in vivo exposure of a poorly water-soluble compound. Int. J. Pharm. 433 (2012), 94–101.
14. [14] Murtaza, G., Solubility enhancement of simvastatin: a review. Acta Pol. Pharm. 69 (2012), 581–590.
15. [15] Zhao, Y., Sun, C., Shi, F., Firempong, C.K., Yu, J., Xu, X., Zhang, W., Preparation, characterization, and pharmacokinetics study of capsaicin via hydroxypropyl-beta-cyclodextrin encapsulation. Pharm. Biol. 54 (2016), 130–138.
16. [16] Fernandes Fraceto, L., Grillo, R., Sobarzo-Sanchez, E., Cyclodextrin inclusion complexes loaded in particles as drug carrier systems. Curr. Top. Med. Chem. 14 (2014), 518–525.
17. [17] Del Valle, E.M., Cyclodextrins and their uses: a review. Process Biochem. 39 (2004), 1033–1046.
18. [18] Stegemann, S., Leveiller, F., Franchi, D., De Jong, H., Lindén, H., When poor solubility becomes an issue: from early stage to proof of concept. Eur. J. Pharm. Sci. 31 (2007), 249–261.
19. [19] Shulman, M., Cohen, M., Soto-Gutierrez, A., Yagi, H., Wang, H., Goldwasser, J., Lee-Parsons, C.W., Benny-Ratsaby, O., Yarmush, M.L., Nahmias, Y., Enhancement of naringenin bioavailability by complexation with hydroxypropoyl-β-cyclodextrin. PloS One, 6, 2011, e18033.
20. [20] Ghosh, A., Biswas, S., Ghosh, T., Preparation and evaluation of silymarin β-cyclodextrin molecular inclusion complexes. J. Young Pharm. 3 (2011), 205–210.
21. [21] Miyake, K., Arima, H., Hirayama, F., Yamamoto, M., Horikawa, T., Sumiyoshi, H., Noda, S., Uekama, K., Improvement of solubility and oral bioavailability of rutin by complexation with 2-hydroxypropyl-β-cyclodextrin. Pharm. Dev. Technol. 5 (2000), 399–407.
22. [22] de Araujo, D.R., Tsuneda, S.S., Cereda, C.M., Carvalho, F.D.G., Preté, P.S., Fernandes, S.A., Yokaichiya, F., Franco, M.K., Mazzaro, I., Fraceto, L.F., Development and pharmacological evaluation of ropivacaine-2-hydroxypropyl-β-cyclodextrin inclusion complex. Eur. J. Pharm. Sci. 33 (2008), 60–71.
23. [23] Vega, E., Egea, M.A., Calpena, A.C., Espina, M., García, M.L., Role of hydroxypropyl-β-cyclodextrin on freeze-dried and gamma-irradiated PLGA and PLGA-PEG diblock copolymer nanospheres for ophthalmic flurbiprofen delivery. Int. J. Nanomed. 7 (2012), 1357–1371.
24. [24] de Paula, W.X., Denadai, Â.M., Santoro, M.M., Braga, A.N., Santos, R.A., Sinisterra, R.D., Supramolecular interactions between losartan and hydroxypropyl-β-CD: ESI mass-spectrometry, NMR techniques, phase solubility, isothermal titration calorimetry and anti-hypertensive studies. Int. J. Pharm. 404 (2011), 116–123.
25. [25] Zhang, P.L., Pan, C.Y., Tang, K.W., Li, H.J., Inclusion behavior of oxybutynin with hydroxypropyl-β-cyclodextrin. J. Central South Univ. Technol. 18 (2011), 1897–1901.
26. [26] Liao, Y., Zhang, X., Li, C., Huang, Y., Lei, M., Yan, M., Zhou, Y., Zhao, C., Inclusion complexes of HP-β-cyclodextrin with agomelatine: preparation, characterization, mechanism study and in vivo evaluation. Carbohydr. Polym. 147 (2016), 415–425.
27. [27] Job, P., Job's method of continuous variation. Ann. Chim. 9 (1928), 113–203.
28. [28] Higuchi, T., Connors, A., Phase-solubility Techniques. 1965.
29. [29] Loftsson, T., Hreinsdóttir, D., Másson, M., Evaluation of cyclodextrin solubilization of drugs. Int. J. Pharm. 302 (2005), 18–28.
30. [30] Ol'khovich, M.V., Sharapova, A.V., Lavrenov, S.N., Blokhina, S.V., Perlovich, G.L., Inclusion complexes of hydroxypropyl-β-cyclodextrin with novel cytotoxic compounds: solubility and thermodynamic properties. Fluid Phase Equilib. 384 (2014), 68–72.
31. [31] Pollard, T.D., A guide to simple and informative binding assays. Mol. Biol. Cell 21 (2010), 4061–4067.
32. [32] Schmidt, H., Kelm, M., Determination of nitrite and nitrate by the Griess reaction. Methods Nitric Oxide Res., 497, 1996.
33. [33] Zhang, J.Q., Jiang, K.M., An, K., Ren, S.H., Xie, X.G., Jin, Y., Lin, J., Novel water-soluble fisetin/cyclodextrins inclusion complexes: preparation, characterization, molecular docking and bioavailability. Carbohydr. Res. 418 (2015), 20–28.
34. [34] Yao, Y., Xie, Y., Hong, C., Li, G., Shen, H., Ji, G., Development of a myricetin/hydroxypropyl-β-cyclodextrin inclusion complex: preparation, characterization, and evaluation. Carbohydr. Polym. 110 (2014), 329–337.
35. [35] Nguyen, T.A., Liu, B., Zhao, J., Thomas, D.S., Hook, J.M., An investigation into the supramolecular structure, solubility, stability and antioxidant activity of rutin/cyclodextrin inclusion complex. Food Chem. 136 (2013), 186–192.
36. [36] Pandit, V., Gorantla, R., Devi, K., Pai, R., Sarasija, S., Preparation and characterization of pioglitazone cyclodextrin inclusion complexes. J. Young Pharm. 3 (2011), 267–274.
37. [37] Wong, J., Yuen, K., Inclusion complexation of artemisinin with α-, β-, and γ-cyclodextrins. Drug Dev. Ind. Pharm. 29 (2003), 1035–1044.
38. [38] Singh, R., Bharti, N., Madan, J., Hiremath, S., Characterization of cyclodextrin inclusion complexes—a review. J. Pharm. Sci. Technol. 2 (2010), 171–183.
39. 1H NMR spectroscopic study of the interaction between cyclodextrins and bicyclo [3.3.1] nonanes. J. Incl. Phenom. Mol. Recognit. Chem. 26 (1996), 209–218.
40. [40] Yang, L.J., Chen, W., Ma, S.-X., Gao, Y.T., Huang, R., Yan, S.J., Lin, J., Host–guest system of taxifolin and native cyclodextrin or its derivative: preparation, characterization, inclusion mode, and solubilization. Carbohydr. Polym. 85 (2011), 629–637.
41. [41] Tang, P., Li, S., Wang, L., Yang, H., Yan, J., Li, H., Inclusion complexes of chlorzoxazone with β-and hydroxypropyl-β-cyclodextrin: characterization, dissolution, and cytotoxicity. Carbohydr. Polym. 131 (2015), 297–305.
42. [42] Nardello-Rataj, V., Leclercq, L., Encapsulation of biocides by cyclodextrins: toward synergistic effects against pathogens. Beilstein J. Org. Chem. 10 (2014), 2603–2622.